BHP Group Limited (BHP): Institutions have left! This can't b...

Institutions have left! This can't be good.

Saving Grace · 2020-04-23T16:09:57.5000000Z

Institutions have left! This can't be good.

Play Episode

4min

Proactive - Interviews for investors

Southern Cross Gold reveals Sunday Creek scale

Southern Cross Gold Consolidated CEO Michael Hudson talked with Proactive at the AIM's Small and Midcap Conference about the company’s focus on gold and antimony exploration in Victoria, Australia, particularly at the Sundae Creek project. Hudson outlined the scale and significance of the discovery, describing it as “one of the most exciting gold discoveries globally… a rare tier one multi-million ounce high grade discovery.” The company is advancing exploration rapidly, with six drill rigs currently operating and plans to expand to eight. Hudson said the company has completed around 70km of drilling and estimates an exploration target of 2.2 to 3.2 million ounces gold equivalent, grading between 8.5 to 10.6 grams per tonne – all within just 5% of the identified trend. Antimony also plays a key role. Hudson explained that China and Russia dominate the global market and recent export bans have highlighted supply vulnerabilities: “You don't have a defense industry without it. And the Western world really doesn't have it. We've got it.” Hudson also reflected on the company’s recent inclusion in the All Ordinaries Index, following the merger of Canadian and Australian entities. He said it marks the first index entry for Southern Cross Gold Consolidated and is “a reflection on a business that's less than three years old.” #SouthernCrossGold #SundayCreek #GoldExploration #Antimony #ASX #MiningStocks #JuniorMiners #ResourceInvesting #MichaelHudson #AllOrdinaries #GoldAndAntimony #AustralianMining

Proactive - Interviews for investors

EBR Systems nears FDA approval for CRT pacemaker

EBR Systems Inc Senior Vice President Andrew Shute talked with Proactive at the AIM maSmall and Midcap Conference about the company’s upcoming FDA decision for its leadless CRT pacemaker system. The device is designed to treat heart failure and represents the only leadless option in a market currently dominated by three players—with no direct competitor. Shute said, “We've developed the world's only leadless pacemaker to treat heart failure. And we're on track to receive FDA approval within the next two and a half weeks.”* The product already holds FDA Breakthrough Device designation, and has shown strong clinical results, including a 16.4% reduction in left ventricular end systolic volume—well above the target goal of 9.3%. Shute outlined the company's go-to-market plan, emphasizing that reimbursement is expected to begin from October 1st under the NTAP and TPT schemes, enabling an ASP of USD 45,000. The company only needs to sell around 2,200 units annually to reach USD 100 million in revenue. “We’ve got no direct competition,” he said. He also highlighted the successful completion of the FDA’s pre-approval inspection with no observations—an uncommon achievement in the medical device industry. The device, supported by data published in JAMA Cardiology, was also featured at the Heart Rhythm Society meeting in 2023. During the interim, the US commercial team will establish purchasing agreements, prepare technology committee engagements, and begin physician training for a limited market release. #EBRSystems #MedicalDevices #HeartFailureTreatment #LeadlessPacemaker #CardiacTech #FDAApproval #CRTDevice #InvestingInHealthcare #BreakthroughDevice #MedTechInnovation #JAMACardiology #HeartRhythmSociety

Proactive - Interviews for investors

SomnoMed lifts revenue 19% amid soaring demand

SomnoMed CO-CEOs Amrita Blickstead and Karen Borg talked with Proactive about the company’s performance and opportunities in the global sleep apnea treatment market. The company, which develops proprietary oral appliances for obstructive sleep apnea, is seeing significant demand as patients seek alternatives to traditional CPAP therapy. “About 60% of people fail to be able to use actual CPAP therapy because it’s quite invasive,” Borg explained. SomnoMed’s devices offer a less intrusive solution and are distributed through dental channels in 28 countries, with strong uptake in the United States and Western Europe. The co-CEOs discussed a major tailwind from the rising use of GLP-1 therapies for weight loss, which is pushing more patients to explore alternative sleep apnea treatments. Increased public awareness of sleep wellness through apps and consumer health trends is also fueling demand. To meet this growth, Blickstead said their immediate focus was on ensuring “the right foundation for profitable growth.” This included strengthening the company’s financial base, reducing costs, paying down debt, and investing heavily in manufacturing. Production capacity has increased by over 40%, with revenue up 19% year-on-year and EBITDA for the first half reaching AUD 5.80 million, compared to a AUD 1.10 million loss previously. Despite these gains, Blickstead noted they are still “chasing our tails and trying to make enough product to continue to grow this business.” #SomnoMed #SleepApnea #OralAppliance #HealthcareInnovation #CPAPAlternative #GLP1 #SleepTech #MedicalDevices #HealthInvesting #ProactiveInvestors

Proactive - Interviews for investors

Light Science Technologies CEO on Injecta Fire Barrier solution to UK's unsafe cladding dilemma

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon talked with Proactive's Stephen Gunnion about the significant opportunity surrounding the company’s Injecta Fire Barrier solution, particularly in light of ongoing fire safety issues in the UK’s residential building sector. Deacon highlighted that the UK still has more than 33,000 buildings between 11m and 18m in height, and over 11,000 high-risk buildings above 18m, that require urgent fire protection measures. He referenced a government estimate suggesting a potential £22 billion cost to address the cladding crisis, which has persisted since the Grenfell tragedy. The Injecta Fire Barrier, acquired in late 2023, offers what Deacon described as a "unique solution"—one that avoids facade removal by injecting fire-resistant material directly into cavities, providing over two hours of fire resistance. He said, "We're three times less in cost and much quicker to install than traditional methods." He noted the division secured £2.7 million in orders during 2024, performing strongly and receiving positive feedback for its efficiency and clean delivery. With an average order value over £500,000 and significant market scope, Deacon framed the opportunity as a scalable revenue driver for the group. The company is targeting £50 million in revenue over the next five years, with Injecta Fire Barrier expected to be a key growth driver. 👉 For more updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #FireSafety #BuildingSafety #InjectaFireBarrier #LightScienceTechnologies #GrenfellLegacy #PropertyInvestment #ConstructionInnovation #FireProtection #CladdingCrisis #UKHousingSafety #ProactiveInvestors #SimonDeacon #BuildingRegulations #RealEstateSafety #PassiveFireProtection

Followers	111
Posts	12401
Boards Moderated	3
Alias Born	01/29/2015

Volume:	2,283,462
Day Range:	47.30 - 48.53
Bid:
Ask:
Last Trade Time:	3:23:17 PM EDT
Total Trades:	31,134

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BHP Detailed Quote

Recent BHP News

More BHP News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BHP News

Go Ad-Free